查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2014531

女性用避孕药市场：依产品类型、作用机制、最终用户年龄及通路划分－2026-2032年全球市场预测

Female Contraceptive Market by Product Type, Mechanism, End User Age, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，女性避孕药具市场价值将达到 105.7 亿美元，到 2026 年将成长至 112.8 亿美元，到 2032 年将达到 175.3 亿美元，复合年增长率为 7.49%。

主要市场统计数据
基准年 2025 105.7亿美元
预计年份：2026年 112.8亿美元
预测年份 2032 175.3亿美元
复合年增长率 (%) 7.49%

策略性介绍，概述了影响女性用避孕决策的临床进展、相关人员的优先事项和获取限制。

在临床创新、医疗服务提供者实践转变以及患者期望不断变化的影响下，女性避孕领域正经历快速的变化。本报告首先简要概述了当前形势，重点介绍了影响所有医疗机构避孕服务取得和应用的临床方法、分销现状、监管压力和实际限制。该报告还将避孕器材和药物选择的最新进展与医疗服务提供者的偏好和患者的决策趋势相结合，为企业高管和临床领导者提供了实用的理论基础。

对临床、监管和数位领域的整合如何重塑整个医疗保健环境中的避孕实践和患者就医途径进行分析概述。

女性避孕格局正受到一系列变革性因素的重塑，这些因素正在改变临床实践、产品研发和病患选择。新型医疗设备设计与长效製剂的出现，拓展了不同生育阶段的临床选择，迫使临床医师重新思考咨商流程与追踪方案。同时，数位健康工具和远端医疗也开始改变避孕咨询、处方和追踪的提供方式，减少了地理限制，并增强了患者在选择避孕方法方面的自主权。

对 2025 年关税调整将如何影响避孕药俱生产和分销的供应链、筹资策略和价格压力进行全面分析。

在2025年的政策环境下，影响进口医药原料和医疗设备组件的关税调整出台，这些变化对采购、价格趋势和供应链结构产生了复杂的影响。使用国际采购的植入式医疗设备电子元件製造商以及依赖海外生产的医药活性成分的製造商立即面临利润率压力，引发了关于近岸外包、供应商多元化和库存策略的讨论。为此，采购负责人和医院系统正在审查与供应商的合同，并考虑建立更长期的采购结构以降低波动风险。

将产品类型、荷尔蒙作用机制、年龄层和分销管道联繫起来的详细细分洞察，揭示了具有临床和商业性相关性的目标机会。

有效的市场区隔能够揭示避孕生态系中临床效益、病患偏好和商业性机会的交会点。产品类型的差异化仍然至关重要。植入、注射剂、子宫内避孕器 (IUD) 和口服避孕药是核心临床类别，每种类别都有其独特的给药途径和依从性特征。在子宫内避孕器中，含铜避孕器和含激素避孕器的差异会影响副作用管理、有效持续时间和医护人员训练。口服避孕药包括复方製剂和单孕激素製剂，其中复方製剂有世代差异。第一代、第二代、第三代和第四代药物各自具有不同的疗效和耐受性，这会影响医生的处方选择。

影响美洲、欧洲、中东和非洲以及亚太地区市场准入、监管途径和分销策略的关键区域趋势和政策差异。

地理因素影响着各地区的医疗服务取得、监管路径和竞争行为，独特的限制和促进因素带来了不同的挑战。在美洲，政策辩论、支付方结构和多元化的医疗服务提供者网络为资源丰富的医疗体系中的快速商业化创造了机会，而服务不足的人群仍然面临着持续的医疗服务获取挑战。儘管地方采购倡议和倡议计画促进了公共医疗机构的采纳，但在高报销环境下，与私人支付方的谈判决定着产品的市场定位。

对製造商、医疗设备专家和灵活的新参与企业如何透过临床证据、伙伴关係和供应链弹性来实现差异化进行实际分析。

竞争格局由成熟的製药公司、专业的医疗设备製造商以及利用服务和数位生态系统提升产品可及性的新兴参与企业组成。主要企业正集中研发精力提升产品的耐受性和易用性，同时投资培训项目，确保医护人员能够正确植入和后续使用医疗器材。製造商与临床网路之间的策略伙伴关係正逐渐成为加速产品普及的有效途径，将产品供应与医护人员培训和病患支援服务结合。

为製造商和医疗保健系统领导者提供可操作的策略重点，以协调证据产生、弹性供应链和管道特定的商业性执行。

产业领导者应采取协作方式，协调各管道的临床证据创建、供应链韧性和商业化过程。首先，应投资于可靠的安全性和耐受性比较数据，这些数据能够直接解决临床医生的担忧并反映患者相关的治疗结果，并将这些证据与简洁易懂、便于临床医生理解的教育模组相结合，从而促进基于器械和长效製剂的治疗方案的顺利应用。其次，应优先考虑供应商多元化，并探索区域製造投资和契约製造伙伴关係，以降低贸易政策波动和原材料成本波动带来的风险。

高度透明的调查方法，结合对关键相关人员的访谈、对监管和临床证据的审查以及供应链分析，可以对策略见解进行多方面的检验。

本研究结合了对临床医生、采购经理、临床专案经理和行业高管的定性访谈，以及对监管申报文件、临床试验註册资料和主要卫生机构发布的公共指南的系统性回顾。受访者的选择旨在涵盖不同的地区、医疗机构和角色，从而提供关于临床实践、采购考量和患者体验的平衡视角。次要分析着重于政策公告、价格调整和供应链指标，并分析其对製造商和采购商的营运影响。

明确的结论揭示了创新、准入障碍以及将产品进步与临床影响联繫起来所需的营运重点之间的关係。

总之，女性用避孕领域面临临床创新和系统性可及性挑战并存的双重困境，需要采取涵盖商业性、临床和营运等多方面的综合应对措施。儘管器械设计和配方方面的进步拓展了终端用户的选择，但其广泛应用取决于临床医生的接受度、分销能力和报销柔软性之间的相互作用。贸易政策的变化和关税调整使得供应链策略和区域生产的重要性日益凸显，进而影响采购行为和产品定位。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：女性用避孕药市场：依产品类型划分

  • 植入式避孕器
  • 注射药物
  • 避孕器
    • 铜子宫内避孕器
    • 荷尔蒙型子宫内避孕器
  • 口服避孕药
    • 复方药片
      • 第一代
      • 第四代
      • 第二代
      • 第三代
    • 仅含黄体素的避孕药

第九章：女性用避孕市场：依机制划分

  • 荷尔蒙系统
    • 复杂类型
    • 单独使用黄体素
  • 非荷尔蒙系统

第十章：女性用

  • 15-24岁
  • 25-34岁
  • 35-49岁

第十一章女性用避孕药市场：依通路划分

  • 诊所
  • 医院药房
  • 网路药房
  • 零售药房

第十二章女性用避孕药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：女性用避孕药市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章女性用避孕药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国女性用避孕药市场

第十六章：中国女性用避孕市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbvie Inc.
  • Acme Generics Pvt. Ltd.
  • Afaxys, Inc.
  • Agile Therapeutics, Inc.
  • Amneal Pharmaceuticals LLC
  • ASKA Pharmaceutical Co., Ltd.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Church & Dwight Co., Inc.
  • Cipla Limited
  • HLL Lifecare Limited
  • Insud Pharma, SL
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Mayne Pharma Group Limited
  • Merck & Co., Inc.
  • Mithra Pharmaceuticals SA
  • Okamoto Industries, Inc.
  • Organon & Co.
  • Perrigo Company PLC
  • Pfizer Inc.
  • Piramal Pharma Ltd.
  • Reckitt Benckiser Group PLC
  • Ritex GmbH
  • Sanofi SA
  • Say It With A Condom, LLC
  • Syzygy Healthcare Solutions LLC
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD, Inc.
  • TTK Healthcare Limited
  • Veru Inc.
  • Viatris Inc.
Product Code: MRR-4348D129FB2D

The Female Contraceptive Market was valued at USD 10.57 billion in 2025 and is projected to grow to USD 11.28 billion in 2026, with a CAGR of 7.49%, reaching USD 17.53 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.57 billion
Estimated Year [2026] USD 11.28 billion
Forecast Year [2032] USD 17.53 billion
CAGR (%) 7.49%

A strategic introduction that frames clinical advances, stakeholder priorities, and access constraints shaping contemporary female contraceptive decision making

The contraceptive landscape for women is undergoing rapid evolution as clinical innovation, shifting provider practices, and changing patient expectations converge. This report opens with a concise framing of the contemporary environment, highlighting clinical modalities, distribution realities, regulatory pressures, and the practical constraints that shape access and adoption across care settings. It sets a pragmatic intellectual baseline for executives and clinical leaders by integrating recent advances in device and pharmaceutical options with observed patterns in provider preferences and patient decision-making.

The introduction contextualizes the competitive environment by emphasizing how technological improvements, patient-centered care models, and supply chain resilience intersect to determine where investment and operational attention are most valuable. It also clarifies the principal stakeholder groups-manufacturers, clinicians, payors, procurement teams, and patient advocacy organizations-and articulates the decision levers each group controls. Taken together, the framing prepares readers to interpret subsequent sections on structural shifts, policy impacts, segmentation nuances, regional dynamics, and recommended actions.

An analytical overview of the converging clinical, regulatory, and digital forces that are reshaping contraceptive practice patterns and patient access across care settings

The landscape for female contraception is being reshaped by a set of transformative forces that alter clinical practice, product development, and patient choice. New device designs and longer-acting formulations have expanded clinical options for different reproductive life stages, prompting clinicians to rethink counseling workflows and follow-up protocols. Concurrently, digital health tools and telemedicine have begun to change how contraceptive counseling, prescription, and follow-up are delivered, reducing geographic friction and enabling more patient autonomy in method selection.

In addition to technological and care-delivery changes, regulatory pathways and evidence expectations have evolved, raising the bar for clinical data but also creating clearer windows for incremental label expansions and novel indications. Competitive dynamics are shifting as firms pursue differentiated value propositions that emphasize ease of use, side effect profiles, and integrated care experiences rather than simple price competition. Finally, payor approaches and public health priorities are increasingly attentive to equity of access and adherence-support programs, encouraging stakeholders to design solutions that address systemic barriers to consistent, appropriate contraceptive use. Together, these shifts demand integrated commercial and clinical strategies that align product differentiation, reimbursement engagement, and provider education to capture sustained uptake.

A comprehensive analysis of how tariff adjustments in 2025 are reshaping supply chains, procurement strategies, and price pressures across contraceptive manufacturing and distribution

The policy environment in 2025 introduced tariff adjustments affecting imported pharmaceutical inputs and device components, and these changes have had compound effects on procurement, pricing dynamics, and supply chain configurations. Manufacturers that rely on internationally sourced electronic components for insertion devices or on active pharmaceutical ingredients produced abroad have faced immediate margin pressure, prompting discussions about nearshoring, supplier diversification, and inventory strategy. Purchasers and hospital systems have responded by revisiting supplier contracts and exploring longer cadence procurement arrangements to mitigate volatility.

These tariff-driven cost pressures have also influenced product lifecycle decisions. Development teams have increasingly prioritized process efficiencies and supplier consolidation to preserve product viability under higher landed costs. At the same time, public health programs and safety-net providers that operate on constrained budgets have sought supplemental funding models or procurement consortia to maintain access, particularly for long-acting reversible contraceptives that require specialized insertion training and device availability. Importantly, several manufacturers accelerated efforts to localize production of critical inputs and to redesign packaging and logistics to reduce cross-border tariff exposure, thereby enhancing resilience and shortening lead times.

From a demand perspective, clinicians and procurement leaders have indicated that even modest increases in delivered cost can influence method counseling preferences in settings where formularies and procurement guidelines are tightly restricted. Consequently, commercial teams must integrate tariff scenarios into procurement negotiations, pricing strategies, and value communications, highlighting total cost of care, adherence benefits, and downstream savings that resonate with payors and institutional buyers. Transitioning supply chains toward diversification and regional capacity represents a multi-year effort but one that is increasingly prioritized to stabilize access and maintain competitive positioning under shifting trade conditions.

In-depth segmentation insights that connect product types, hormonal mechanisms, age cohorts, and distribution channels to reveal targeted opportunities for clinical and commercial alignment

Effective segmentation illuminates where clinical benefit, patient preference, and commercial opportunity intersect within the contraceptive ecosystem. Product type distinctions remain essential: implants, injectables, intrauterine devices, and pills represent core clinical categories with distinct administration pathways and adherence profiles. Within intrauterine devices, the distinction between copper and hormonal options carries implications for side effect management, duration of effectiveness, and provider training. Pills encompass combined and progestin-only formulations, and within combined options there are generational differences-first, second, third, and fourth generation agents each present unique efficacy and tolerability trade-offs that influence prescriber selection.

Mechanism-based segmentation further clarifies demand dynamics by separating hormonal approaches from non-hormonal choices, and recognizing that hormonal options bifurcate into combined and progestin-only formulations with different contraindication profiles and counseling needs. Age-based end-user segmentation captures life-stage considerations: those aged 15 to 24 prioritize autonomy, convenience, and privacy; the 25 to 34 cohort often balances family planning goals with career and lifestyle considerations; and the 35 to 49 group places greater emphasis on long-term effectiveness, comorbidity considerations, and transition to non-hormonal alternatives as appropriate. Distribution channels shape access pathways, with clinics, hospital pharmacies, online pharmacies, and retail pharmacies each presenting distinct friction points and opportunities for education, adherence support, and aftercare.

Integrating these segmentation lenses reveals where targeted interventions can improve adoption and continuity. For example, long-acting modalities may resonate strongly with older age bands seeking minimal maintenance, while digital counseling and mail-order delivery can substantially lower access barriers for younger users who value discretion. Similarly, tailoring communications to mechanism-specific safety considerations and ensuring that distribution channels are equipped to support insertion or administration are critical operational priorities. By aligning product differentiation, clinical evidence generation, and channel enablement to the intersecting axes of product type, mechanism, age, and distribution, stakeholders can deploy more precise and effective strategies that address both clinical outcomes and user experience.

Key regional dynamics and policy contrasts across the Americas, Europe Middle East Africa, and Asia-Pacific that shape access, regulatory pathways, and distribution strategies

Geographic dynamics influence access, regulatory pathways, and competitive behavior across distinct regions, each presenting unique constraints and enablers. In the Americas, policy debates, payer structures, and diverse provider networks create both opportunities for rapid commercialization in well-resourced systems and ongoing access challenges in underserved populations. Regional procurement initiatives and advocacy programs have shaped uptake in public health clinics, while private payor negotiations dictate product positioning in higher-reimbursement settings.

Europe, Middle East & Africa presents a complex tapestry of regulatory environments and capacity differences. Some countries within this broad region have highly centralized procurement and stringent regulatory harmonization, enabling coordinated rollouts when approvals align. Other markets are fragmented, with variable clinical practice patterns and infrastructure that affect the feasibility of device-dependent contraceptives. Access programs and international donor initiatives remain influential in enabling broader distribution, especially for long-acting reversible methods in low-resource settings.

Asia-Pacific encompasses markets with substantial manufacturing capacity alongside rapidly evolving domestic demand. Regulatory agencies in several jurisdictions have accelerated reviews of contraceptive products and fostered local production capabilities, which can reduce lead times and exposure to international trade perturbations. However, cultural factors, provider practice norms, and heterogeneous reimbursement landscapes continue to shape adoption curves. Across all regions, stakeholders must adapt commercialization strategies to local regulatory structures, distribution ecosystems, and the policy priorities that influence procurement and patient access.

A practical analysis of how manufacturers, device specialists, and agile entrants are differentiating through clinical evidence, partnerships, and supply chain resilience

The competitive environment is populated by a mix of legacy pharmaceutical firms, specialized device manufacturers, and newer entrants leveraging service and digital ecosystems to enhance access. Leading firms focus R&D on improving tolerability and ease of use while investing in training programs to ensure clinician competence for device insertion and follow-up. Strategic partnerships between manufacturers and clinical networks have emerged as a pragmatic way to accelerate adoption, combining product supply with provider education and patient support services.

Smaller, agile companies are differentiating through novel delivery mechanisms, patient engagement tools, and targeted niche strategies aimed at specific age cohorts or clinical subpopulations. Contract manufacturing and component suppliers have also become pivotal players as firms seek to de-risk supply chains and maintain production flexibility. Additionally, procurement consortia and group purchasing organizations have increased their influence by negotiating longer-term supply agreements, which emphasizes the importance of predictable supply and value-based contracting for commercial success.

Across the competitive set, successful companies are those that link product attributes to demonstrable clinical and economic benefits, invest in post-market surveillance and real-world evidence, and create integrated value propositions that include clinician training and patient support. Operational excellence in manufacturing, regulatory strategy, and distribution is equally critical, as disruptions in any of those areas can quickly erode confidence among institutional buyers and clinicians.

Actionable strategic priorities for manufacturers and health system leaders to align evidence generation, resilient supply chains, and channel-specific commercial execution

Industry leaders should pursue a coordinated approach that aligns clinical evidence generation, supply chain resilience, and channel-specific commercialization. First, invest in robust comparative safety and tolerability data that speak directly to clinician concerns and patient-relevant outcomes, and pair that evidence with concise, clinician-friendly education modules to accelerate comfortable adoption of device-based and long-acting options. Second, prioritize supplier diversification and consider regional manufacturing investments or contract manufacturing partnerships to reduce exposure to trade policy shifts and input cost volatility.

Third, tailor go-to-market strategies to distribution realities by enabling clinics with insertion training and stocking solutions, supporting hospital pharmacies with formulary dossiers and total cost of care arguments, and optimizing online channels for privacy-focused younger cohorts through discreet packaging and telehealth-enabled counseling. Fourth, engage proactively with payors and public health purchasers using value narratives that emphasize continuity of care, reduced unintended pregnancies, and lifecycle adherence support rather than unit price alone. Finally, embed real-world evidence programs and post-market safety monitoring to sustain regulatory confidence and to refine product positioning over time. Taken together, these actions create a durable platform for growth that balances clinical credibility with operational resilience and channel effectiveness.

A transparent methodology combining primary stakeholder interviews, regulatory and clinical evidence review, and supply chain analysis to triangulate strategic insights

This research synthesizes primary qualitative interviews with clinicians, procurement directors, clinical program managers, and industry executives, coupled with a structured review of regulatory filings, clinical trial registries, and publicly available guidance from major health authorities. Interview subjects were selected to represent diverse geographies, care settings, and roles to provide a balanced view of clinical practice, procurement considerations, and patient experience. Secondary analysis focused on policy announcements, tariff changes, and supply chain indicators to contextualize operational implications for manufacturers and buyers.

Data synthesis employed thematic analysis to identify cross-cutting trends and causal linkages between policy, supply chain resilience, clinical adoption, and patient behavior. Case studies were used to illustrate successful interventions in provider training, procurement strategies, and channel enablement. Where appropriate, sensitivity considerations were discussed to highlight how changes in trade policy, regulatory requirements, or clinical guidelines could alter recommended priorities. The methodology emphasizes transparency in source types and triangulation across multiple evidence streams to support the strategic recommendations presented in this report.

A decisive conclusion drawing the connections between innovation, access barriers, and the operational priorities necessary to translate product advances into clinical impact

In conclusion, the female contraceptive space presents a blend of clinical innovation and systemic access challenges that require integrated commercial, clinical, and operational responses. Advances in device design and formulation expand options for end users, but adoption depends on the interplay of clinician comfort, distribution capacity, and reimbursement flexibility. Trade policy shifts and tariff adjustments have heightened the importance of supply chain strategy and regional production considerations, which in turn influence procurement behavior and product positioning.

To navigate this environment, stakeholders should prioritize evidence that aligns with clinician concerns, invest in resilient supply chains, and tailor channel strategies to the lived realities of different end-user cohorts. Coordinated cross-functional planning that connects R&D, regulatory affairs, commercial strategy, and supply chain management will be essential to translate product innovations into sustained access and clinical benefit. The insights in this report are intended to inform those decisions and to provide a practical foundation for targeted investments and partnerships.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Female Contraceptive Market, by Product Type

  • 8.1. Implants
  • 8.2. Injectables
  • 8.3. Intrauterine Devices
    • 8.3.1. Copper IUD
    • 8.3.2. Hormonal IUD
  • 8.4. Pills
    • 8.4.1. Combined Pill
      • 8.4.1.1. First Generation
      • 8.4.1.2. Fourth Generation
      • 8.4.1.3. Second Generation
      • 8.4.1.4. Third Generation
    • 8.4.2. Progestin Only Pill

9. Female Contraceptive Market, by Mechanism

  • 9.1. Hormonal
    • 9.1.1. Combined
    • 9.1.2. Progestin Only
  • 9.2. Non-Hormonal

10. Female Contraceptive Market, by End User Age

  • 10.1. 15-24 Years
  • 10.2. 25-34 Years
  • 10.3. 35-49 Years

11. Female Contraceptive Market, by Distribution Channel

  • 11.1. Clinics
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Retail Pharmacies

12. Female Contraceptive Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Female Contraceptive Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Female Contraceptive Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Female Contraceptive Market

16. China Female Contraceptive Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbvie Inc.
  • 17.6. Acme Generics Pvt. Ltd.
  • 17.7. Afaxys, Inc.
  • 17.8. Agile Therapeutics, Inc.
  • 17.9. Amneal Pharmaceuticals LLC
  • 17.10. ASKA Pharmaceutical Co., Ltd.
  • 17.11. Aurobindo Pharma Limited
  • 17.12. Bayer AG
  • 17.13. Church & Dwight Co., Inc.
  • 17.14. Cipla Limited
  • 17.15. HLL Lifecare Limited
  • 17.16. Insud Pharma, S.L.
  • 17.17. Johnson & Johnson Services, Inc.
  • 17.18. Lupin Limited
  • 17.19. Mayne Pharma Group Limited
  • 17.20. Merck & Co., Inc.
  • 17.21. Mithra Pharmaceuticals S.A.
  • 17.22. Okamoto Industries, Inc.
  • 17.23. Organon & Co.
  • 17.24. Perrigo Company PLC
  • 17.25. Pfizer Inc.
  • 17.26. Piramal Pharma Ltd.
  • 17.27. Reckitt Benckiser Group PLC
  • 17.28. Ritex GmbH
  • 17.29. Sanofi S.A.
  • 17.30. Say It With A Condom, LLC
  • 17.31. Syzygy Healthcare Solutions LLC
  • 17.32. Teva Pharmaceutical Industries Ltd.
  • 17.33. TherapeuticsMD, Inc.
  • 17.34. TTK Healthcare Limited
  • 17.35. Veru Inc.
  • 17.36. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FEMALE CONTRACEPTIVE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FEMALE CONTRACEPTIVE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COPPER IUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL IUD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY PILL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY PROGESTIN ONLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 15-24 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 25-34 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY 35-49 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 165. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 167. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 168. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 169. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 194. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 195. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 196. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 201. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 202. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 203. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 204. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 205. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL FEMALE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY INTRAUTERINE DEVICES, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY PILLS, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY COMBINED PILL, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY END USER AGE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA FEMALE CONTRACEPTIVE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)